![FIGURE 2. | Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy | Journal of Nuclear Medicine FIGURE 2. | Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/50/9/1394/F2.large.jpg)
FIGURE 2. | Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy | Journal of Nuclear Medicine
![MP11-16 PROSTATE-SPECIFIC ANTIGEN ANALYSES IN PROPEL: ABIRATERONE AND OLAPARIB VERSUS ABIRATERONE AND PLACEBO AS FIRST-LINE THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Journal of Urology MP11-16 PROSTATE-SPECIFIC ANTIGEN ANALYSES IN PROPEL: ABIRATERONE AND OLAPARIB VERSUS ABIRATERONE AND PLACEBO AS FIRST-LINE THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Journal of Urology](https://www.auajournals.org/cms/asset/210c1c4b-9d96-4590-9a5c-9560eb702201/ju.0000000000003226.16t1.gif)
MP11-16 PROSTATE-SPECIFIC ANTIGEN ANALYSES IN PROPEL: ABIRATERONE AND OLAPARIB VERSUS ABIRATERONE AND PLACEBO AS FIRST-LINE THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Journal of Urology
![Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen | NEJM Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2003/nejm_2003.349.issue-4/nejmoa021659/production/images/img_medium/nejmoa021659_t1.jpeg)
Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen | NEJM
![Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer. | Semantic Scholar Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ac4ab721c7e17a9b1cb04ea629b66a283e875bd1/4-Table2-1.png)
Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer. | Semantic Scholar
![ASCO GU 2022: Survival Outcomes and Characterization of Patients With Metastatic Castration-Sensitive Prostate Cancer Undergoing Intensified ADT Who Do Not Achieve an Optimal PSA Response (PSA ≤0.2 Ng/ML) ASCO GU 2022: Survival Outcomes and Characterization of Patients With Metastatic Castration-Sensitive Prostate Cancer Undergoing Intensified ADT Who Do Not Achieve an Optimal PSA Response (PSA ≤0.2 Ng/ML)](https://www.urotoday.com/images/com-doc-importer/49-asco-gu-2022/asco-gu-2022-survival-outcomes-and-characterization-of-patients-pts-with-metastatic-castration-sensitive-prostate-cancer-mcspc-undergoing-intensified-androgen-deprivation-therapy-adt-who-do-not-achieve-an-optimal-psa-response-psa-0-2-ng-ml/image-1.jpg)
ASCO GU 2022: Survival Outcomes and Characterization of Patients With Metastatic Castration-Sensitive Prostate Cancer Undergoing Intensified ADT Who Do Not Achieve an Optimal PSA Response (PSA ≤0.2 Ng/ML)
![Table 1 from Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. | Semantic Scholar Table 1 from Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/577f03549114cbc8eaed925e2546c1a723e0b3e1/5-Table1-1.png)